Key result
Thiazolidinedione therapy was associated with a lower incidence of congestive heart failure compared to non-TZD therapy in male veterans with type 2 diabetes (HR 0.69; 95% CI 0.60-0.79).
Why the study?
Does thiazolidinedione therapy reduce the incidence of congestive heart failure in male veterans with type 2 diabetes?
Cohort (n=3,956)
Yes
Does thiazolidinedione therapy reduce the incidence of congestive heart failure in male veterans with type 2 diabetes?
Hazard Ratio: 0.69 (95% CI 0.6–0.79)
In a retrospective cohort of male veterans with type 2 diabetes, TZD therapy was associated with a significantly lower incidence of congestive heart failure compared to non-TZD therapy, contrasting with previous randomized trial findings.
Should not change practice in type 2 diabetes; hypothesis-generating and contrasts prior randomized findings.
Aim: The thiazolidinedione (TZD) class of antihyperglycaemic agents has been shown to improve glycaemic control by improving peripheral insulin sensitivity but may worsen or precipitate congestive heart failure (CHF). Randomized controlled trials have shown an increased risk of CHF in patients treated with TZDs. The use of TZDs in clinical practice has the potential to increase morbidity and health care costs. The purpose of this study was to compare the incidence of CHF in TZD and non‐TZD‐treated patients in a clinical setting. Methods: A retrospective cohort study of all male patients with type 2 diabetes seen in the South Central US Veterans Administration health care network between 1 October 1996 and 31 December 2004. We constructed a Cox proportional hazards model to evaluate the impact of TZD therapy on time to incidence of CHF. Results: Of 3956 patients, 29% (n = 1157) developed CHF during the study period. The incidence of CHF was higher in patients who received TZD medications than in those who received TZDs. After adjustment for multiple cardiac risk factors, the hazard ratio for the development of CHF for TZD versus non‐TZD‐treated patients was 0.69 with a 95% confidence interval of 0.60–0.79. Conclusions: Patients in this cohort who received TZD medications had a lower incidence of heart failure than patients who did not receive TZDs.
No takes yet. Share an insight, caveat, or question.
Toprani et al. (2010) conducted a cohort in Type 2 diabetes (n=3,956). Thiazolidinediones (TZDs) vs. Non-TZD therapy was evaluated on Incidence of congestive heart failure (CHF) (HR 0.69, 95% CI 0.60-0.79). Thiazolidinedione therapy was associated with a lower incidence of congestive heart failure compared to non-TZD therapy in male veterans with type 2 diabetes (HR 0.69; 95% CI 0.60-0.79).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: